SCHEMBL6510310

SCHEMBL6510310

COc1ccc(CSCCOCCOCCO)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
PKM P14618 1/20 0.45
APP P05067 3/20 0.43
MAPT P10636 2/20 0.41
CYP3A4 P08684 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
KMT2A Q03164 1/20 0.41
SLCO1B3 Q9NPD5 1/20 0.41
SLCO1B1 Q9Y6L6 1/20 0.41
GAA P10253 1/20 0.40
DAO P14920 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6518055 1.00 IDO1 (0.45) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL6512047 0.98 IDO1 (0.46) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL17230505 0.87 SMN1; SMN2 (0.47) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL6512863 0.84 ALDH1A1 (0.42) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL6511578 0.84 TAAR1 (0.47) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL8841048 0.83 IDO1 (0.53) IDO1ALDH1A1SMN1; SMN2PKMAPP
SCHEMBL6509444 0.82 ALDH1A1 (0.47) IDO1ALDH1A1SMN1; SMN2PKMMAPT
SCHEMBL6422414 0.80 CYP2C19 (0.49) ALDH1A1SMN1; SMN2CYP3A4LMNAMEN1
SCHEMBL6511575 0.79 ALDH1A1 (0.47) IDO1ALDH1A1SMN1; SMN2PKMMAPT
SCHEMBL16093231 0.78 APP (0.57) IDO1ALDH1A1SMN1; SMN2APPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050192430-A1 Linker arms for nanocrystals and compounds thereof ROSENTHAL SANDRA J (US) 2005-09-01 US disclosed
US-20030129590-A1 Linker arms for nanocrystals and compounds thereof NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-10 US disclosed
WO-2001090716-A2 LINKER ARMS FOR NANOCRYSTALS AND COMPOUNDS THEREOF VANDERBILT UNIVERSITY (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030129590-A1 Linker arms for nanocrystals and compounds thereof SCO2, NCL, NCAPH IDO1 2344/4885ALDH1A1 2277/4885SMN1; SMN2 1359/4885
US-20050192430-A1 Linker arms for nanocrystals and compounds thereof NCL, CHN2, SCO2 IDO1 1815/4885ALDH1A1 3030/4885SMN1; SMN2 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.